170 related articles for article (PubMed ID: 21615719)
21. Haematopoietic stem cell transplant activity in Switzerland 1997/1998: a report by the STABMT. Swisstransplant Working Group Blood and Marrow Transplantation.
Schweiz Med Wochenschr; 2000 Jul; 130(27-28):1027-33. PubMed ID: 10953852
[TBL] [Abstract][Full Text] [Related]
22. Ewing's sarcoma and the development of secondary malignancies.
Fuchs B; Valenzuela RG; Petersen IA; Arndt CA; Sim FH
Clin Orthop Relat Res; 2003 Oct; (415):82-9. PubMed ID: 14612633
[TBL] [Abstract][Full Text] [Related]
23. Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies.
Adhikari J; Sharma P; Bhatt VR
Future Oncol; 2015; 11(23):3175-85. PubMed ID: 26551415
[TBL] [Abstract][Full Text] [Related]
24. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases.
O'Brien TA; Eastlund T; Peters C; Neglia JP; Defor T; Ramsay NK; Scott Baker K
Br J Haematol; 2004 Oct; 127(1):67-75. PubMed ID: 15384979
[TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics of patients with lymphoproliferative disorders after allogeneic hematopoietic stem cell transplant].
Gu B; Chen GH; Wang Y
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1046-9. PubMed ID: 23363801
[No Abstract] [Full Text] [Related]
26. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation.
Hasegawa W; Pond GR; Rifkind JT; Messner HA; Lau A; Daly AS; Kiss TL; Kotchetkova N; Galal A; Lipton JH
Bone Marrow Transplant; 2005 Jan; 35(1):51-5. PubMed ID: 15516939
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
[TBL] [Abstract][Full Text] [Related]
28. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
[TBL] [Abstract][Full Text] [Related]
29. Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).
Hertenstein B; Hambach L; Bacigalupo A; Schmitz N; McCann S; Slavin S; Gratwohl A; Ferrant A; Elmaagacli A; Schwertfeger R; Locasciulli A; Zander A; Bornhäuser M; Niederwieser D; Ruutu T;
Haematologica; 2005 Jul; 90(7):969-75. PubMed ID: 15996934
[TBL] [Abstract][Full Text] [Related]
30. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
Petersen EJ; Lokhorst HL; Verdonck LF
Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
[TBL] [Abstract][Full Text] [Related]
31. Oral malignancies following HSCT: graft versus host disease and other risk factors.
Demarosi F; Lodi G; Carrassi A; Soligo D; Sardella A
Oral Oncol; 2005 Oct; 41(9):865-77. PubMed ID: 16084755
[TBL] [Abstract][Full Text] [Related]
32. Haematopoietic stem cell transplantation for thalassaemia major in Hong Kong: prognostic factors and outcome.
Li CK; Shing MM; Chik KW; Lee V; Leung TF; Cheung AY; Yuen MP
Bone Marrow Transplant; 2002 Jan; 29(2):101-5. PubMed ID: 11850702
[TBL] [Abstract][Full Text] [Related]
33. Association of squamous cell carcinoma of the oral cavity in allogeneic hematopoietic stem cell transplant recipients.
Reddy NM; Sullivan MA; Hahn TE; Battiwalla M; Smiley SL; McCarthy PL
Bone Marrow Transplant; 2007 Nov; 40(9):907-9. PubMed ID: 17724441
[No Abstract] [Full Text] [Related]
34. Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature.
Wang E; Hutchinson CB; Huang Q; Lu CM; Crow J; Wang FF; Sebastian S; Rehder C; Lagoo A; Horwitz M; Rizzieri D; Yu J; Goodman B; Datto M; Buckley P
Am J Clin Pathol; 2011 Apr; 135(4):525-40. PubMed ID: 21411775
[TBL] [Abstract][Full Text] [Related]
35. The presence of functional CCR5 and EBV reactivation after allogeneic haematopoietic stem cell transplantation.
Bogunia-Kubik K; Jaskula E; Lange A
Bone Marrow Transplant; 2007 Jul; 40(2):145-50. PubMed ID: 17530006
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
37. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S
Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991
[TBL] [Abstract][Full Text] [Related]
38. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation.
McCarthy AJ; Kingman HM; Kelly C; Taylor GS; Caul EO; Grier D; Moppett J; Foot AB; Cornish JM; Oakhill A; Steward CG; Pamphilon DH; Marks DI
Bone Marrow Transplant; 1999 Dec; 24(12):1315-22. PubMed ID: 10627641
[TBL] [Abstract][Full Text] [Related]
39. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
Bogunia-Kubik K; Mlynarczewska A; Jaskula E; Lange A
Br J Haematol; 2006 Feb; 132(3):326-32. PubMed ID: 16409297
[TBL] [Abstract][Full Text] [Related]
40. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.
Shaw BE; Mufti GJ; Mackinnon S; Cavenagh JD; Pearce RM; Towlson KE; Apperley JF; Chakraverty R; Craddock CF; Kazmi MA; Littlewood TJ; Milligan DW; Pagliuca A; Thomson KJ; Marks DI; Russell NH
Bone Marrow Transplant; 2008 Dec; 42(12):783-9. PubMed ID: 18724393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
